VIENNA — In a stunning smack-down the marginal threat of Asian competition in Europe suddenly became a menacing, in-your-face confrontation.
As the doors to the exposition floor opened at 10 a.m. on Day Two of the European Congress of Radiology (ECR) visitors found themselves streaming into Asia Alley, a pinched corridor flanked on either side by Mindray (Shenzhen, China) and Samsung (Seoul, Korea).
Despite the regulatory approval of new antiepileptic drugs (AED) over the past decade and the expansion of indications deemed suitable for epilepsy surgery, individuals with intractable seizures – roughly one in three epilepsy patients – still face a dearth of treatment options. That void is all the more frustrating because epilepsy remains a debilitating condition for reasons beyond the clinical manifestations, often resulting in chronic unemployment or underemployment, social isolation and poor socioeconomic status. It's no surprise, then, that the prospect of a new treatment for people with medically refractory epilepsy would be greeted with great enthusiasm. As an adjunct...
RSS
